Skip to search formSkip to main contentSkip to account menu

LCZ 696

Known as: LCZ-696, LCZ696 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (3)

AminobutyratesAngiotensin Receptor AntagonistsTetrazoles

Narrower (3)

Entrestosacubitrilsacubitril / valsartan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun.
Backgound: Current drug therapy for the management of arterial hypertension and heart failure has provided substantial benefits… 
2017
2017
Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment
.
OBJECTIVES To assess the protein binding and pharmacokinetics of sacubitril/valsartan analytes (sacubitril, sacubitrilat, and… 
Review
2016
Review
2016
Natriuretic peptides and their therapeutic potential in heart failure treatment: An updated review.
Brain natriuretic peptide (BNP), also known as a B-type natriuretic peptide, is one of the important biomarkers with a proven… 
Review
2016
Review
2016
Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?
Review
2016
Review
2016
Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date
Heart failure is a global problem with elevated prevalence, and it is associated with substantial cardiovascular morbidity and… 
2015
2015
Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice
Heart failure represents a primary cause of morbidity and mortality in older people and despite significant therapeutic advances… 
Review
2015
Review
2015
Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
2013
2013
Attenuation of increased secretory leukocyte protease inhibitor, matricellular proteins and angiotensin II and left ventricular remodeling by candesartan and omapatrilat during healing after…
While secretory-leukocyte-protease-inhibitor (SLPI) may promote skin wound healing, its role in infarct healing after reperfused… 
Review
2013
Review
2013
New drug therapies interfering with the renin–angiotensin–aldosterone system for resistant hypertension
There is a persistent need for the development of new antihypertensive drugs, because the control of blood pressure is still not… 
Review
2013
Review
2013
Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition
Introduction: Cardiovascular disease is the leading cause of death worldwide, accounting for 30% of all deaths, with elevated… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)